[go: up one dir, main page]

WO2000062805A8 - A method of reversing thymic atrophy - Google Patents

A method of reversing thymic atrophy

Info

Publication number
WO2000062805A8
WO2000062805A8 PCT/US2000/010008 US0010008W WO0062805A8 WO 2000062805 A8 WO2000062805 A8 WO 2000062805A8 US 0010008 W US0010008 W US 0010008W WO 0062805 A8 WO0062805 A8 WO 0062805A8
Authority
WO
WIPO (PCT)
Prior art keywords
reversing
cytokines
cell
thymic atrophy
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/010008
Other languages
French (fr)
Other versions
WO2000062805A1 (en
Inventor
Barton F Haynes
Gregory D Sempowski
Dhavalkumar D Patel
John S Sundy
Laura P Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Priority to AU44595/00A priority Critical patent/AU4459500A/en
Publication of WO2000062805A1 publication Critical patent/WO2000062805A1/en
Publication of WO2000062805A8 publication Critical patent/WO2000062805A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates, in general, to cytokines and, in particular, to a method of reconstituting the T cell arm of a mammalian immune system in those diseases or conditions in which the T cell pool is damaged. More specifically, the present invention relates to a method of reversing thymic atrophy associated aging and to a method of treating T cell lymphopenia. The methods comprise administering cytokines, agonists thereof, that are underproduced in these physiological states and/or administering antagonists of cytokines that are overproduced.
PCT/US2000/010008 1999-04-15 2000-04-14 A method of reversing thymic atrophy Ceased WO2000062805A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44595/00A AU4459500A (en) 1999-04-15 2000-04-14 A method of reversing thymic atrophy by administering an antagonist of an overproduced cytokine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12936199P 1999-04-15 1999-04-15
US60/129,361 1999-04-15

Publications (2)

Publication Number Publication Date
WO2000062805A1 WO2000062805A1 (en) 2000-10-26
WO2000062805A8 true WO2000062805A8 (en) 2001-01-25

Family

ID=22439598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010008 Ceased WO2000062805A1 (en) 1999-04-15 2000-04-14 A method of reversing thymic atrophy

Country Status (2)

Country Link
AU (1) AU4459500A (en)
WO (1) WO2000062805A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030519A2 (en) * 2002-09-30 2004-04-15 Duke University Thymic atrophy
JP5709356B2 (en) 2006-01-13 2015-04-30 アメリカ合衆国 Codon optimized IL-15 and IL-15R-α genes for expression in mammalian cells
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
EP0737071A1 (en) * 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof

Also Published As

Publication number Publication date
WO2000062805A1 (en) 2000-10-26
AU4459500A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
WO1998007745A3 (en) Compositions and methods for treating infections using analogues of indolicidin
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
ZA88798B (en) Dental anti-plaque and anti-caries agent
WO1992018160A3 (en) Method for inhibiting adhesion of white blood cells to endothelial cells
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
SG149000A1 (en) Gag binding proteins
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
BG103016A (en) Polypeptides capable of forming antigen-binding structures of specificity to rhesus d antigens, their encoding dna and method for their prparation and application
GB2367061A (en) Peptides
IS2819B (en) Vascular adhesion molecules and formulation of their activity @
CA2186423A1 (en) Protein which induces interferon-gamma production by immunocompetent cell
MY110327A (en) Anti-thrombin polypeptides
WO2002058589A3 (en) Agents and methods for promoting bone growth
WO2003081246A8 (en) Treatment of congestive heart failure with natriuretic peptide and a diuretic
WO1995030001A3 (en) Novel p-selectin ligand protein
GR3036287T3 (en) Substituted imidazo(4,5-b)pyridines and benzimidazoles as angiotensin II antagonistes.
WO2000062805A8 (en) A method of reversing thymic atrophy
WO2003063775A3 (en) Methods and compositions for the promotion of hair growth utilizing actin binding peptides
WO2004005317A3 (en) Thrombin peptide derivative dimers
ATE374246T1 (en) POLYPEPTIDE FRAGMENTS WITH A C-TERMINAL PART OF CATALASE FROM HELICOBACTER
IE860212L (en) Polypeptide factors from colostrum
WO1998022580A3 (en) Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation
WO2000043026A3 (en) Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP